We’re immensely proud of our portfolio. We partner with companies, often in the early stage, to build strong management teams and to ensure our CEOs and entrepreneurs have access to our network and resources to accelerate the advancement of their assets.
Brandon BioCatalyst plays an active, ‘hands on’ role, working closely with the Member Institutes to identify promising opportunities, ‘working them up’, completing due diligence and in many cases, assisting with the establishment of the start-up company. Importantly, we then guide early-stage investments through the development process to next round financing, a trade-sale, partnering, an IPO or into stand-alone, growing businesses. Brandon BioCatalyst invests in opportunities originating from its member medical research institutes or research hospitals. Each Member Institute selects a representative for Brandon BioCatalyst’s Investment Review Committee (IRC), the body which provides a peer review assessment of investment proposals.
To date, Brandon BioCatalyst has supported more than 50 promising start-up companies, with more than 85 percent of them founded by the first investment from Brandon BioCatalyst .
Combining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectDeveloping a novel therapy for the treatment of Meibomian Gland Dysfunction
View ProjectDeveloping novel anti-fibrotic therapies for the treatment of scarring associated with chronic kidney disease
View ProjectTargeting fibrotic and inflammatory indications associated with type 2 diabetes and metabolic syndrome with an initial focus on liver fibrosis
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectDeveloping vaccines that target the major virulence factors produced by the bacterium Porphyromonas gingivalis (P gingivalis)
View ProjectDeveloping therapies for patients with cardiac rhythm diseases and heart failure using wireless cardiac stimulation
View ProjectDeveloping therapies for respiratory infections in patients with asthma and COPD
View ProjectGeorge Medicines is an innovative late-stage drug development company focused on the large, expanding and underserved market for the management of non-communicable diseases (NCDs)
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View Project